Key facts
- This page summarizes Katina Dorton's Form 4 filing for Prelude Therapeutics Inc (PRLD).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 10 Jun 2026, 16:15.
Katina Dorton - 09 Jun 2026 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)
- Reporting relationship
- Director
- Issuer ticker
- PRLD
- Reported as of
- 09 Jun 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Jun 2026, 16:15:43 UTC
- Prior SEC filing
- 04 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Bryant D. Lim, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Katina Dorton filed Form 4 for Prelude Therapeutics Inc (PRLD) on 10 Jun 2026.
Change
- Previous filing in this sequence was filed on 04 Jun 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001617541
Primary reporting owner
Dorton Katina
- Relationship
- Director
- Address
- C/O PRELUDE THERAPEUTICS INCORPORATED, 175 INNOVATION BOULEVARD, WILMINGTON
- Signature
- /s/ Bryant D. Lim, Attorney-in-Fact
- Signature date
- 10 Jun 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PRLD
transaction
Derivative
Director Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +38,000
- Change %
- Price
- $0.000000*
- Shares after
- 38,000
- Date
- 09 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 38,000
- Exercise price
- $3.94
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.